Blog grid

16 Jan

Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early

In oncology drug development, FDA rejection is often perceived as a late-stage failure, an FDA Complete Response Letter...
14 Jan

6 Oncology Drugs Likely to Receive FDA Approval in 2026: A Clinical and Regulatory Analysis

Each year, the oncology development landscape becomes noisier. Late-stage assets are promoted aggressively, conference headlines amplify early signals,...
Nageatte Ibrahim at the event
23 Sep

Arc Nouvel Showcases Innovation at BioTechX USA in Philadelphia

Arc Nouvel Debuts in Philadelphia at BioTechX USA with an Exhibitor Booth featured in the Start-Up Zone of the conference...
Nageatte Ibrahim poster
08 Sep

She’s Gone and Done It: The Inspiring Journey of Dr. Nageatte Ibrahim

At the crossroads of medicine, science, and innovation stands Dr. Nageatte Ibrahim—a physician, scientist, and global leader whose...

Contact us Now

Follow Us